Early treatment with a biosimilar agent increased total costs by £70 (US $89) per patient versus standard intervention.
In patients with rheumatoid arthritis (RA), early treatment with biologics can have substantial benefits; anti—tumor necrosis factor (anti-TNF) therapies, for example, increase the likelihood of remission and slow radiographic progression. The cost of biologics, however, means that many patients lack access to these agents.
In a newly published paper, a team of authors sought to assess the cost-effectiveness of early treatment with biologics—either reference or biosimilar—in patients who do not respond adequately to conventional drugs.
Using a Markov model to estimate lifetime patient costs, the researchers compared standard intervention (adding an anti-TNF agent to methotrexate after 12 months) with 2 early intervention options (adding an anti-TNF reference at 6 months or adding an anti-TNF biosimilar at 6 months).
Adding a reference anti-TNF agent after 6 month of methotrexate increased costs by £4701 (US $5978) per patient versus the standard intervention but decreased lifetime direct costs (such as medical costs) and indirect costs (such as loss of work productivity) by £3008 (US $3826) per patient. Overall, this intervention yielded a net cost increase of £1692 (US $2151) per patient.
Adding a biosimilar anti-TNF agent resulted in the same changes in lifetime direct and indirect costs, but resulted in a lower increase in treatment cost at £3078 (US $3914) per patient. Compared with standard intervention, total costs were increased in this scenario by £70 (US $89) per patient.
There was an increase of 0.10 quality-adjusted life years (QALYs) in patients who received early treatment, from 5.4 QALYs for the standard intervention to 5.5 QALYs for early therapy.
Early intervention versus standard intervention was shown to be cost-effective at a threshold of £30,000 (US $38,147) per QALY, with incremental cost-effectiveness ratios (ICERs) of £17,335 (US $22,042) per QALY for reference anti-TNF agents and £713 (US $907) per QALY with biosimilars.
While additional research is warranted, say the authors, this analysis is an important first step in research on early biologic therapy for patients with RA, and suggest that early biologic or biosimilar intervention is cost-effective and carries very low ICERs.
Reference
Patel D, Shelbaya A, Cheung R, Aggarwal J, Park SH, Coindreau J. Cost-effectiveness of early treatment with originator biologics or their biosimilars after methotrexate failure in patients with established rheumatoid arthritis [published online May 30, 2019]. Adv Ther. doi: 10.1007/s12325-019-00986-7.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.